Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

In This Article:

Disc Medicine Inc
Disc Medicine Inc
  • Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF)

  • Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications

  • Management will host a conference call during the ASH meeting on Sunday, December 8 at 9:00pm EST / 6:00pm PST

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, CA on December 7-10, 2024.

“We’re delighted to be presenting such a robust set of data at ASH showcasing the significant progress we’ve made across our entire portfolio. At the meeting, we’ll be providing clinical updates on each of our core development programs, setting us up for the next stages of development in EPP, MF and polycythemia vera,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “In addition, we look forward to sharing translational data from preclinical studies in new indications such as anemia of inflammatory bowel disease (DISC-0974) and sickle cell disease (DISC-3405), providing further evidence of the broad potential of Disc’s programs.”

Management will host a call during the ASH meeting to review highlights of the presented data and plans for next steps in development on Sunday, December 8 at 9:00pm EST / 6:00pm PST. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).

Details of Presentations and Abstracts:

The full abstracts are now available through the ASH conference website. Pursuant to Disc Medicine practice, the clinical study abstracts published today contain previously presented data; new data and analyses are reserved for presentation at the conference.

DISC-0974 Oral Presentation:

Abstract Number: 657
Title: A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
Date / Time: Sunday, December 8, 5:00pm PST
Presenting Author: Naseema Gangat, M.B.B.S.

Bitopertin Poster Presentations:

Publication Number: 1089
Title: Results from the AURORA Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria
Date / Time: Saturday, December 7, 5:30pm – 7:30pm PST
Presenting Author: Amy Dickey, M.D., MSc

Waiting for permission
Allow microphone access to enable voice search

Try again.